Nadia Heydari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nadia Heydari has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Seyyed Mehdi Jafari
Metabolic Disorders Research Center, Biomedical Research Institute, Golestan University of Medical Sciences, Gorgan, Iran
2 shared publications - Farzin Sadeghi
Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
1 shared publication - Hadi Parsian
Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
1 shared publication - Mahmoud Reza Aghamaali
Department of Biology, Faculty of Sciences, University of Guilan, Rasht, Iran
1 shared publication - Mahsa Mahdizadeh
Metabolic Disorders Research Center, Biomedical Research Institute Golestan University of Medical Sciences, Gorgan, Iran; Department of Biochemistry and Biophysics, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
1 shared publication - Zahra Arab-Bafrani
Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran
1 shared publication
Latest Publications
- Open Access
- 1 July 2024
- Published by InkVista Publishing House
- Vol. 12 (2) , 1-4
Changes in Claudin-4 expression and tight junction integrity in human esophageal cancer: A Systematic Review
Background: Esophageal cancer is one of the most common cancers worldwide. Because this disease is usually diagnosed in advanced stages, its treatment is challenging and the survival rate of patients is relatively low. One of the parts that is disturbed in the tumor tissue of esophageal cancer is the tight ...
- 1 July 2024
- Published by InkVista Publishing House
- Vol. 12 (2) , 1-4
Open AccessChanges in Claudin-4 expression and tight junction integrity in human esophageal cancer: A Systematic Review
Background: Esophageal cancer is one of the most common cancers worldwide. Because this disease is usually diagnosed in advanced stages, its treatment is challenging and the survival rate of patients is relatively low. One of the parts that is disturbed in the tumor tissue of esophageal cancer is the tight ...
- 26 June 2023
- Published by Springer Nature in Medical Oncology
- Vol. 40 (8) , 1-7
The evolving landscape of involvement of DTYMK enzymes in cancer
Cancer cells require continuous synthesis of nucleotides for their uncontrolled proliferation. Deoxy thymidylate kinase (DTYMK) belongs to the thymidylate kinase family and is concerned with pyrimidine metabolism. DTYMK catalyzes the ATP-based conversion of deoxy-TMP to deoxy-TDP in both de novo and salvage pathways. Different studies demonstrated that DTYMK was increased in various types of cancers such as hepatocellular carcinoma, colon cancer, lung cancer, etc. Increased level of DTYMK was associated with poorer survival and prognosis, stage, grade and size of tumor, cell proliferation, colony formation, enhanced sensitivity to chemotherapy drugs, migration. Some studies were showed that knockdown of DTYMK reduced the signaling pathway of PI3K/AKT and downregulated expression of CART, MAPKAPK2, AKT1 and NRF1. Moreover, some microRNAs could suppress DTYMK expressions. On the other hand based on the TIMER database, the infiltration of macrophages, dendritic cells, neutrophils, B cells, CD4+ T cell and CD8+ T cell is affected by DTYMK. In the present review, we describe the genomic location, protein structure and isoforms of DTYMK and focus on its role in cancer development.
- 26 June 2023
- Published by Springer Nature in Medical Oncology
- Vol. 40 (8) , 1-7
The evolving landscape of involvement of DTYMK enzymes in cancer
Cancer cells require continuous synthesis of nucleotides for their uncontrolled proliferation. Deoxy thymidylate kinase (DTYMK) belongs to the thymidylate kinase family and is concerned with pyrimidine metabolism. DTYMK catalyzes the ATP-based conversion of deoxy-TMP to deoxy-TDP in both de novo and salvage pathways. Different studies demonstrated that DTYMK was increased in various types of cancers such as hepatocellular carcinoma, colon cancer, lung cancer, etc. Increased level of DTYMK was associated with poorer survival and prognosis, stage, grade and size of tumor, cell proliferation, colony formation, enhanced sensitivity to chemotherapy drugs, migration. Some studies were showed that knockdown of DTYMK reduced the signaling pathway of PI3K/AKT and downregulated expression of CART, MAPKAPK2, AKT1 and NRF1. Moreover, some microRNAs could suppress DTYMK expressions. On the other hand based on the TIMER database, the infiltration of macrophages, dendritic cells, neutrophils, B cells, CD4+ T cell and CD8+ T cell is affected by DTYMK. In the present review, we describe the genomic location, protein structure and isoforms of DTYMK and focus on its role in cancer development.
- 3 February 2021
- Published by Wiley in The Journal of Gene Medicine
- Vol. 23 (4) , e3320
Circulating status of microRNAs 660‐5p and 210‐3p in breast cancer patients
Background: MicroRNAs (miRs), which are stable in the blood, comprise small non‐coding RNAs that regulate gene expression. They have important roles in almost all biological pathways, especially in cancer‐relevant processes, and have an abnormal expression in breast cancer. In recent studies, the aberrant expression level of various microRNAs has been demonstrated in human cancer. In the present study, the status of serum microRNA‐210‐3p and microRNA‐660‐5p expression levels in breast cancer patients was determined compared to healthy controls.Methods: Serum samples were collected from 40 newly diagnosed breast cancer patients and 40 healthy controls. A real‐time quantitative polymerase chain reaction was utilized to detect the expression levels of these microRNAs. Data analysis was conducted with p < 0.05 being considered statistically significant.Results: The data obtained showed that serum levels of miR‐660‐5p and miR‐210‐3p were significantly up‐regulated in breast cancer patients compared to healthy controls (p < 0.001 and p = 0.001, respectively). In addition, significant up‐regulation was observed in the early stage (in situ, stage I and II) of breast cancer patients (n = 25) compared to healthy (n = 40) controls (p < 0.001 and p < 0.05, respectively). Receiver‐operating characteristic curve analysis indicated that the serum miR‐660‐5p and miR‐210‐3p levels have reasonable sensitivity (79% and 68%) and specificity (61% and 51%) for the detection of breast cancer patients (area under the receiver‐operating curve = 0.774 and 0.716, respectively).Conclusions: Although the results show a reasonable diagnostic accuracy of these microRNAs for detection of breast cancer in this small and preliminary study, further large‐scale studies are essential to confirm the presented results.
- 3 February 2021
- Published by Wiley in The Journal of Gene Medicine
- Vol. 23 (4) , e3320
Circulating status of microRNAs 660‐5p and 210‐3p in breast cancer patients
Background: MicroRNAs (miRs), which are stable in the blood, comprise small non‐coding RNAs that regulate gene expression. They have important roles in almost all biological pathways, especially in cancer‐relevant processes, and have an abnormal expression in breast cancer. In recent studies, the aberrant expression level of various microRNAs has been demonstrated in human cancer. In the present study, the status of serum microRNA‐210‐3p and microRNA‐660‐5p expression levels in breast cancer patients was determined compared to healthy controls.Methods: Serum samples were collected from 40 newly diagnosed breast cancer patients and 40 healthy controls. A real‐time quantitative polymerase chain reaction was utilized to detect the expression levels of these microRNAs. Data analysis was conducted with p < 0.05 being considered statistically significant.Results: The data obtained showed that serum levels of miR‐660‐5p and miR‐210‐3p were significantly up‐regulated in breast cancer patients compared to healthy controls (p < 0.001 and p = 0.001, respectively). In addition, significant up‐regulation was observed in the early stage (in situ, stage I and II) of breast cancer patients (n = 25) compared to healthy (n = 40) controls (p < 0.001 and p < 0.05, respectively). Receiver‐operating characteristic curve analysis indicated that the serum miR‐660‐5p and miR‐210‐3p levels have reasonable sensitivity (79% and 68%) and specificity (61% and 51%) for the detection of breast cancer patients (area under the receiver‐operating curve = 0.774 and 0.716, respectively).Conclusions: Although the results show a reasonable diagnostic accuracy of these microRNAs for detection of breast cancer in this small and preliminary study, further large‐scale studies are essential to confirm the presented results.